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Background: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate
initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which
is recognized by third-generation but not by second-generation PTH immunoassays. In normal
individuals, the third-generation to second-generation PTH ratio should be less than 1.
Objective:Our objectivewas to study the utility of the third-generation to second-generation PTH
ratio as a means of distinguishing PCa patients (n  24) from control groups with and without
disorders of calcium secretion, including patients on renal hemodialysis (n 74), postrenal trans-
plantation (n  60), and primary hyperparathyroidism (PHP; n  30).
Setting and Design: We conducted a retrospective, laboratory-based study at tertiary referral
academic centers.
Results: The mean third-generation to second-generation ratio was 0.58  0.10 in the dialysis
patients, 0.54 0.10 in the renal transplant group, 0.54 0.12 in the elderly healthy patients, and
0.68  0.11 in the PHP group. All 245 of these patients presented a PTH third-generation to
second-generation ratio of less than 1. In contrast, we observed an inverted third-generation to
second-generation PTH ratio of more than one in 20 PCa patients, whereas only four PCa patients
had a normal ratio of less than 1.
Conclusions:An inverted third-generation to second-generationPTHratiooccurred in themajority
of patients with advanced PCa and was absent in all 245 relevant controls. A third-generation to
second-generation PTH ratio higher than 1 had a sensitivity of 83.3% and a specificity of 100%
among PHP patients as a marker for PCa. This ratio may be useful to identify patients with PCa
earlier and todetect patients either at risk of developing PCaor those inwhomrecurrence is taking
place. (J Clin Endocrinol Metab 95: 0000–0000, 2010)
Parathyroid carcinoma (PCa) is a rare disease, compris-ing 0.005% of all cancers (1). Fewer than 400 PCa
cases were reported before 1993 (2), and in the U.S. Na-
tional Cancer Database, only 286 cases have been de-
scribed over 10 yr (3). PCa accounts for less than 1% of
sporadic primary hyperparathyroidism (PHP) and is as-
sociated with more severe clinical features than parathy-
roid adenomas (4). The severe hypercalcemia due to un-
controlled PTH hypersecretion is the main cause of
morbidity and death in patients with PCa.
Differentiating PCa from more common parathyroid
adenomas is often challenging, particularly because the
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histopathology of parathyroid tumors can be equivocal
(5). Indeed, the definitive diagnosis of PCa is largely made
only when recurrence or metastasis occurs. Because sur-
gery remains the only curative treatment for PCa and be-
cause better outcomes are associated with complete resec-
tion of the tumor at the time of initial surgery, a correct
initial diagnosis is important. Hence, a biological marker
that could help to reliably distinguish PCa from parathy-
roid adenoma would be useful.
The first assays used to measure PTHwere RIAs. They
recognized the full-length PTH1-84 but also a large amount
of various C-terminal fragments. Since 1987, routine de-
terminations of so-called intact PTH have used various
immunometric methods. These immunoassays (com-
monly termed second-generationPTHimmunoassays)use
a pair of antibodies, a capture antibody directed against
the (39–84) portion of the PTH molecule and a second
antibody that recognizes the (13–24) portion of the pep-
tide. They not only recognize PTH1-84 but also cross-react
to varying degrees (50–100%) with a family of large ami-
no-truncated fragments, of which PTH7-84 is the most
abundant form (6). Because PTH7-84 accumulates in pa-
tients suffering from chronic kidney disease, this explains,
in part, the PTH overestimation in secondary hyperpara-
thyroidism due to chronic renal failure (7, 8). Another
generationof PTH immunoassays appeared in1999 (third
generation). The third-generation PTH immunoassays
used similar capture antibodies as the second-generation
immunoassays but added an anti-N-terminal antibody di-
rected against the first four amino acids of PTH (9). These
immunoassays, therefore, do not measure the PTH7-84
fragment.Amino-PTH,a recently recognized formofPTH
that is not truncated but modified in the (15–20) region,
potentially by phosphorylation of a serine residue at po-
sition 17 (10), cross-reacts with these third-generation
PTH kits but not with antibodies used in most second-
generation immunoassays.
Physiologically, PTH7-84 represents 15–50%and amino-
PTH less than 10% of circulating PTH1-84 (10). There-
fore, in healthy individuals, the ratio between the amounts
of PTH measured with third- vs. second-generation immu-
noassays, the third-generation to second-generationPTHra-
tio [(PTH1-84amino-PTH)/(PTH1-84PTH7-84)]will not
be greater than 1. Recently, it has been shown that amino-
PTH is overproduced in PCa (11, 12) and in some rare
cases of severe PHP (13). In such patients, the third-gen-
eration to second-generation PTH ratio may be inverted
(1) as compared with normal individuals (1). Data
from small patient series have suggested that the third-
generation to second-generation PTH ratiomay have clin-
ical utility to discriminate PCa from most cases of benign
PHP (12).
The current study was undertaken to assess the third-
generation to second-generation PTH ratio in a large pop-
ulation of patients suffering from advanced PCa and com-




Twenty-four patients from Europe, the United States, and
Australia with advanced PCa were included (Table 1). All had
previously undergone surgery and had been admitted to local
hospitals for anticancer immunotherapy (14, 15). All underwent
assessments of PTH levels before immunotherapy using second-
and third-generation immunoassays to derive a third-generation
to second-generation PTH ratio.
We recruited a representative comparator group to permit
assessments of the third-generation to second-generation PTH
ratio as a discriminatory test. The first subgroup was a popula-
tion of 73 chronic renal failure patients (65.2  16.5 yr; 38%
female) undergoing hemodialysis at the Centre Hospitalier Uni-
versitaire de Lie`ge. We evaluated 30 patients with PHP (53.8
14.3 yr; 77% female), 60 renal transplant patients (50.6 12.2
yr; 45% female), and 82 consecutive healthy elderly individuals
(62.0  8.0 yr; 53% female).
The studywas approved by the Institutional ReviewBoard of
the Centre Hospitalier Universitaire de Lie`ge, and all patients
provided informed consent for immunotherapy treatment.
PTH immunoassays
PTHwas determinedwith theDuo PTH immunoradiometric
kit from Scantibodies Laboratory (Santee, CA). This kit includes
two different immunoassays: 1) a second-generation PTH im-
munoassay that recognizes PTH1-84 and the non-PTH1-84 com-
ponents but not amino-PTH;2) a third-generation immunoassay
that recognizes PTH1-84 and amino-PTH. These two immu-
noassays were calibrated against the same PTH standard. In
our laboratory’s experience, the inter- and intraassay coeffi-
cients of variation obtained with these two immunoassays are
less than 10%.
Statistics
Statistical analysis was carried out by the Medcalc Software
(Mariakerke, Belgium). Differences between groups were calcu-
lated by the Student’s independent-samples t test, with P value
0.05 indicating a significant difference.
Results
The results of the second-generation and third-generation
PTH immunoassays and the third-generation to second-
generation ratios are summarized in Table 1. All 245
control subjects had a third-generation to second-gener-
ation PTH ratio of less than 1 (Fig. 1). The mean third-
generation to second-generation ratio was 0.58 0.10 in
dialysis patients, 0.54  0.10 in the renal transplant
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group, 0.54  0.12 in the elderly healthy patients, and
0.68 0.11 in the PHP group. Themean third-generation
to second-generation PTH ratio was similar in the nor-
mal elderly and renal transplanted patients. The ratio
was significantly higher in the hemodialysis group com-
pared with the renal transplant patients (P  0.05).
Patients with parathyroid adenoma had an increased
ratio comparedwith the three comparative control pop-
ulations (P  0.0001).
An inverted third-generation to second-generation
PTH ratio (1) was seen in 20 PCa patients, whereas
four patients had a normal ratio of less than 1 (Fig. 1).
The mean third-generation to second-generation ratio
(1.40  0.46) was significantly higher among the PCa
patients than all control populations. Importantly, the
mean third-generation to second-generation ratio in the
PCa group was significantly higher than the ratio in
PHP patients (P  0.0001).
Discussion
PTH circulates as a mixture of PTH1-84 and various ami-
no-truncated fragments. These fragments not only are
products of degradation of PTH1-84 but are also secreted
by the parathyroid gland itself. Experimental studies have
suggested that PTH7-84 is implicated in the PTH resistance
observed in chronic kidney disease by antagonizing the
calcemic actions of PTH in ratswithnormal renal function
(16, 17) or by interacting with a novel PTH receptor via
the C-terminal region (18, 19). With the advent of the
third-generation PTH immunoassays, a new circulating
form of PTH, amino-PTH, was discovered. It is still un-
knownwhether this amino-PTH is biologically active, but
it has previously been shown to be overproduced in PCa
(11, 12) and rarely in cases of severe PHP (13). This over-
production leads to an inversion of the third-generation to
second-generation PTH ratio, which is normally less than
1. In the current study, we demonstrate that an inverted
third-generation to second-generation PTHratiowas seen
in 83% of PCa patients compared with 0% of a series of
four relevant control populations.
The current study of the third-generation to second-
generation PTH ratio as a marker for PCa is the largest to
address this important question in this very rare malig-
nancy. Previously, Caron et al. (12) observed an inverted
third-generation to second-generation PTH ratio (1) in
a patient with PCa and in only one of 30 and none of 294
osteoporotic patients with andwithout PHP, respectively.
In the PHP patient from that study, the inverted ratio re-
mained after surgery (1.54), and the patient exhibited




















1 F 59 42 3.69 261 435 1.66 11.1 Y (lung)
2 M 63 61 3.10 464 544 1.17 15.2 Y (lung)
3a M 36 31 2.89 814 668 0.82 8.8 Y (lymph node)
4 M 58 55 3.13 188 333 1.77 9.7 Y (mediastinum)
5a F 55 53 2.96 452 361 0.80 8.6 N
6 F 65 60 4.62 367 487 1.33 9.7 N
7 M 76 68 3.34 1098 1363 1.24 9.2 Y (lung)
8 M 57 52 4.03 806 1101 1.37 11.8 Y (lung)
9 M 55 49 3.47 828 888 1.07 11.4 Y (lung)
10 M 53 43 3.72 606 768 1.27 13.4 Y (mediastinum, bone)
11a M 70 62 3.40 695 438 0.63 11.8 N
12 M 55 52 4.16 622 691 1.11 15.4 Y (lung)
13 F 66 60 4.30 185 370 2.00 8.3 Y (tracheostomy site)
14 F 58 51 4.10 230 638 2.78 12.7 N
15 M 62 55 2.74 71 99 1.40 17.3 Y (N/A)
16 F 52 43 2.92 272 365 1.34 8.4 Y (N/A)
17 F 42 28 4.56 363 583 1.61 21.2 Y (esophagus)
18 F 50 48 3.57 628 810 1.29 18.0 Y (left thyroid gland)
19 M 68 65 2.98 404 542 1.34 15.6 Y (N/A)
20 F 72 69 4.00 1063 1989 1.87 4.0 Y (esophagus)
21 M 77 68 2.92 197 358 1.82 37.4 N
22 M 58 55 3.10 99 102 1.03 10.1 Y (liver)
23 F 35 34 4.85 747 1076 1.44 12.8 Y (N/A)
24a F 61 58 4.00 145 114 0.79 11.0 N/A
F, Female; M, male; N, no; N/A, not available; Y, yes.
a Patients with a third-generation to second-generation PTH ratio (1).
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marginal hypercalcemia over the course of 3 yr follow-up,
which suggests continuing unresolved parathyroid gland
dysfunction. Blachowicz et al. (20) reported similar results
with zero of 32 patients with PHP exhibiting an inverted
third-generation to second-generation PTH ratio. In a
larger study of cinacalcet therapy, Rubin et al. (11) re-
ported that of eight patients with PCa studied, four (50%)
had an inverted ratio. This study also showed that when
cinacalcet lowered PTH, the inverted ratio remained un-
changed. This contrasts with surgical treatment when the
ratio may revert to less than 1 (13).
In our study, we found the third-generation to second-
generation PTH ratio to be systematically less than 1
among a group of 245 subjects that included 73 hemodi-
alysis patients, 60 renal transplant patients, 82 healthy
elderly patients, and 30 PHP patients. Assessing the var-
ious published data as a whole, the prevalence of an in-
verted third-generation to second-generation PTH ratio is
very low in PHP patients (1.6%; one in 61) and has never
been reported in non-PHP controls (0%; zero in 530). In
marked contrast, the frequency of an inverted third-gen-
eration to second-generation PTH ratio in the PCa pop-
ulation is much higher. Combining the current data with
those in the literature, an inverted ratio occurred in 25 of
33 (75.8%) PCa patients reported.We observed a normal
PTH ratio in four of 24 PCa patients,
whereas Rubin and colleagues noted
four of eight such patients (11). Taken
together, data from the current study
and the published literature indicate
that an inverted third-generation to sec-
ond-generation PTH ratio has a sensi-
tivity of 75.8% and a specificity of
98.9% among PHP patients as a tumor
marker for PCa (11, 12, 20).
Our results are derived from patients
suffering from advanced PCa. It would
be important to evaluate the sensitivity
and specificity of the PTH ratio in PCa
patients with a less advanced stage of
malignancy. A useful application would
be the ability to identify patients with
PCa at an early stage, when the difficulty
in distinguishing these challenging cases
from severe benign parathyroid ade-
noma patients ismost pronounced. Also,
a prospective longitudinal study is neces-
sary to capture the PTH ratio in a large
group of PHP patients presurgically to
determine whether those with a persis-
tently inverted PTH ratio are at a greater
risk of evolving into PCa. Another cru-
cial point is whether transformation of a
severe benign parathyroid adenoma to a carcinoma is asso-
ciated with a change from a normal to an inverted ratio.
Further investigation of the characteristics of PCa patients
with a normal ratio (and PHP patients with an elevated
ratio)will be necessary to determinewhether any refinement
can be undertaken to improve the sensitivity above 80%.
The nature of the increased ratio and its relationship to the
secretion of amino-PTH and other forms of PTH by PCa
cells needs to be characterized in absolute terms by detailed
molecular chemical analyses. Whether genetic factors such
as HRPT2 mutation status play a role in determining the
forms and relative amounts of PTH secreted (and hence the
third-generation to second-generation PTH ratio) remains
to be determined.
In conclusion, the diagnosis and follow-up of PCa is
challenging. Our results, based on a large cohort of PCa
patients, shows that an inverted third-generation to sec-
ond-generation PTH ratio may have clinical utility as a
tumor marker for PCa, as suggested in previous smaller
series. Further investigations are needed to assess the re-
lationships between an elevated ratio or inversion of a
previously normal ratio and the risk of developing PCa or
the relapse of a previously treated PCa. The third-gener-
ation to second-generation PTH ratio may also be useful
FIG. 1. Box-and-whisker plot of PTH ratio as measured by third- and second-generation PTH
immunoassays in the control groups and in patients with parathyroid adenoma and PCa. The
central box represents the values from the lower to upper quartile (25–75th percentile). The
middle line represents the median. A line extends from the minimum to the maximum value,
excluding outside values (values that are above/below the lower quartile  1.5 times the
interquartile range). The third-generation to second-generation PTH ratio was significantly
higher in the hemodialysis group compared with the renal transplanted group (P 0.05). PHP
patients had increased ratios compared with the other three control populations (P 0.0001),
but this was significantly lower than the ratio observed in PCa patients (P 0.0001).
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as a follow-up tool in operated patients to identify those
with persistent disease. However, the relationship be-
tween a third-generation to second-generation PTH ratio
higher than 1 and clinical disease characteristics requires
further study before its utility as a screening tool and sur-
rogate efficacy measure in PCa can be fully confirmed.
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